Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, Bank of America reiterated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a top large-cap biotech pick for 2026, with a $598 price objective. The firm stated the company’s cystic fibrosis franchise has the ability to generate cash flow to support pipeline growth. BofA also cited the rare kidney disease franchise as a major long-term growth engine, citing encouraging results for povetacicept in IgA nephropathy.

In a similar vein, Argus boosted Vertex’s price target to $520 on March 19, highlighting the improved performance of its cystic fibrosis brand, especially triple-combination medicines like Trikafta/Kaftrio and the expanding Alyftrek regimen.

The ratings come around a timeline where the United States Food and Drug Administration approved Vertex Pharmaceuticals’ expanded use of ALYFTREK for treating patients with cystic fibrosis aged 6 and up. The label extension was backed up by clinical and/or in vitro results from 564 variants responding to ALYFTREK and 521 variants responding to TRIKAFTA.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.

While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.